scholarly journals The Progress of Antitumor Interstitial Treatment Strategy of Malignant Ovarian Cancer

2013 ◽  
Vol 01 (04) ◽  
pp. 19-23
Author(s):  
振超 郭
Keyword(s):  
Ovarian Cancer ◽  
Treatment Strategy

The impact of staging laparoscopy on treatment strategy in advanced ovarian cancer

2016 ◽  
Vol 206 ◽  
pp. 256-257
Author(s):  
Borut Kobal ◽  
Branko Cvjeticanin ◽  
Matija Barbič ◽  
Leon Meglič ◽  
Erik Škof ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Treatment Strategy ◽  
Advanced Ovarian Cancer ◽  
Staging Laparoscopy ◽  
The Impact

Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.

1998 ◽  
Vol 16 (5) ◽  
pp. 1849-1851 ◽  
Author(s):  
M Markman ◽  
P G Rose ◽  
E Jones ◽  
I R Horowitz ◽  
A Kennedy ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Treatment Strategy ◽  
Randomized Study ◽  
Advanced Ovarian Cancer ◽  
Primary Carcinoma ◽  
Primary Therapy ◽  
Prolonged Infusion ◽  
Fallopian Tube Cancer ◽  
Improve Outcome

PURPOSE To test the hypothesis that prolonged infusion of paclitaxel (96 hours) might overcome resistance to shorter infusion schedules (3 or 24 hours) in ovarian cancer. PATIENTS AND METHODS A total of 30 patients with advanced ovarian cancer (24 patients), primary carcinoma of the peritoneum (four patients), or fallopian tube cancer (two patients) who previously had received paclitaxel administered on either a 3-hour or 24-hour schedule were treated with the agent delivered as a 96-hour infusion (30 to 35 mg/m2/d x 4 days) on an every 3-week program. RESULTS Although the regimen generally was well tolerated, no objective responses were observed. CONCLUSION In patients with ovarian cancer who have shown resistance to shorter paclitaxel infusion schedules, ninety-six hour infusional paclitaxel is an inactive treatment strategy. This makes it less likely that protracted infusion of paclitaxel will improve outcome when used as part of primary therapy of ovarian cancer. An ongoing randomized study will answer that question.

Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer

2016 ◽  
Vol 72 (1) ◽  
pp. 6-11 ◽  
Author(s):  
E. De Jaeghere ◽  
K. Vandecasteele ◽  
K. Claes ◽  
A. Makar ◽  
P. Tummers ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Treatment Strategy ◽  
Parp Inhibitors ◽  
Clinical Routine ◽  
Tailored Treatment
Sign in / Sign up

Export Citation Format

Share Document